<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525238</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-091</org_study_id>
    <secondary_id>2011-005225-40</secondary_id>
    <nct_id>NCT01525238</nct_id>
  </id_info>
  <brief_title>PK Study of Dapagliflozin in Pediatric Subjects With T2DM</brief_title>
  <official_title>A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin
      in pediatric subjects with type 2 diabetes mellitus (T2DM)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary purpose: The primary purpose is to assess the pharmacokinetics of a single dose of
      Dapagliflozin in the range of 2.5 to 10 mg in pediatric subjects aged 10 to 17 years with
      T2DM
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2012</start_date>
  <completion_date type="Actual">September 1, 2014</completion_date>
  <primary_completion_date type="Actual">September 1, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of Dapagliflozin over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Time of maximum observed plasma concentration (Tmax) for Dapagliflozin was derived from plasma concentrations versus time data. Medians were reported in hours (h).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Dapagliflozin</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from time zero extrapolated to infinite time was derived from concentration versus time data. Geometric means are reported in nanogram hours per milliliter (ng*hr/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Dapagliflozin</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of Dapagliflozin over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Plasma Half-life (T-HALF) of Dapagliflozin</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Plasma half-life (T-Half) for Dapagliflozin was derived from plasma concentrations versus time data. Means are reported in hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Apparent Clearance After Extravascular Administration (CL/F) of Dapagliflozin</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Apparent clearance after extravascular administration (CL/F) of Dapagliflozin was derived from plasma concentrations versus time data. Geometric means are reported in milliliters per minute (mL/min).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean of Apparent Volume of Distribution at Terminal Phase After Extravascular Administration (Vz/F) of Dapagliflozin</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Geometric mean of apparent volume of distribution at terminal phase after extravascular administration of Dapagliflozin was derived from plasma concentration versus time data. Geometric means are reported in Liters (L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin 3-O-Glucuronide</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of Dapagliflozin 3-O-Glucuronide over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin 3-O-Glucuronide</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Time of maximum observed plasma concentration (Tmax) for Dapagliflozin 3-O-Glucuronide was derived from plasma concentrations versus time data. Medians were reported in hours (h).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Dapagliflozin 3-O-Glucuronide</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from time zero extrapolated to infinite time was derived from concentration versus time data. Geometric means are reported in nanogram hours per milliliter (ng*hr/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Dapagliflozin 3-O-Glucuronide</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of Dapagliflozin 3-O-Glucuronide over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Half-life (T-HALF) of Dapagliflozin 3-O-Glucuronide</measure>
    <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
    <description>Plasma half-life (T-Half) for Dapagliflozin was derived from plasma concentration versus time data. Means are reported in hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Fasting Plasma Glucose Concentrations at Pre-dose on Day 1 and on Day 2 After an 8-hr Fasting</measure>
    <time_frame>Day 1 (Pre-dose) to Day 2</time_frame>
    <description>Plasma glucose concentrations were evaluated in all treated subjects at Day 1 pre-dose and at Day 2 after fasting for 8 hours. Means are reported in milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Fasting Plasma Glucose From Baseline Until Day 2</measure>
    <time_frame>Day 1 (Pre-dose) to Day 2</time_frame>
    <description>Plasma glucose concentrations were evaluated in all treated subjects at Day 1 pre-dose and at Day 2 after fasting for 8 hours. Mean change from baseline to Day 2 is reported in milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Total Amount of Glucose Excreted in Urine Over 24 Hours</measure>
    <time_frame>Time of dose to 24 hours post-dose, Day 1 to Day 2</time_frame>
    <description>The total amount of glucose excreted in urine was measured for 24 hours following administration of Dapagliflozin. Means are reported in grams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Sign Abnormalities, Electrocardiogram (ECG) Abnormalities, or Physical Examination Abnormalities Following Study Drug Administration.</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Participants were followed from dosing on Day 1 until study discharge on Day 3. The number of participants with investigator-assessed clinically-important abnormalities in vital sign measurements, ECGs or physical examinations was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Hematology Laboratory Abnormalities</measure>
    <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
    <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose (Day -1). Lab values that met the following criteria were marked as abnormalities: Hemoglobin (grams per deciliter:g/dL): &lt;0.85*Pre-Rx. Hematocrit (%): &lt;0.85*Pre-Rx. Platelet Count (x10^9 cells per liter:c/L): &lt;0.85*LLN or &gt;1.5*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx). Leukocytes (x10^3 cells per microliter: c/uL): &lt;0.9*LLN, &gt;1.2*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx or &gt;ULN, if Pre- Rx&gt;ULN, use &gt;1.15*Pre-Rx or &lt;LLN). Neutrophils (Absolute) (x10^3 c/uL): &lt;=1.5. Lymphocytes (Absolute) (x10^3 c/uL): &lt;0.75 or &gt;7.5. Monocytes (Absolute) (x10^3 c/uL): &gt;2.000. Basophils (x10^3 c/uL): &gt;0.4. Eosinophils (Absolute) (x10^3 c/uL): &gt;0.75. Blasts (Absolute) (x10^9 c/L) &gt; 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Serum Chemistry Abnormalities</measure>
    <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
    <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx). Bilirubin (milligrams per deciliter: mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx). Blood Urea Nitrogen (mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.2*Pre-Rx). Creatinine (micromoles per Liter (umol/L)): &gt;1.5*ULN if Pre-Rx missing or &lt;= ULN, &gt;1.33*Pre-Rx if PreRx &gt; ULN. Sodium (mmol/L): &gt;1.05*ULN, 1.05*Pre-Rx if Pre-Rx&gt;ULN: &lt;0.95*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.05*Pre-Rx, &lt;LLN). Potassium(mmol/L), Chloride (mmol/L), Calcium(mmol/L): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN). Phosphorus (mg/dL): &lt;0.85*LLN, &gt;1.25*ULN (if Pre-Rx&lt;LLN, &lt;0.85*Pre-Rx, &gt;ULN. if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx, &lt;LLN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Abnormalities in Other Chemistry Testing</measure>
    <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
    <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Glucose, fasting serum (mmol/L): &lt;0.8*LLN, &gt;1.3*ULN (if Pre-Rx&lt;LLN: &lt;0.8*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;2.0*Pre-Rx, &lt;LLN). Protein (grams per deciliter: g/L): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN). Albumin (g/L): &lt;0.9*LLN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx). Uric Acid (mmol/L): &gt;1.2*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx). Lactate Dehydrogenase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Urinalysis Abnormalities</measure>
    <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
    <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Blood, urine (Qualitative): &gt;=2 (If Pre-Rx &gt;= 1, &gt;=2*Pre-Rx). Glucose, urine (Qualitative): &gt;=1, (If Pre-Rx &gt;=1, &gt;=2*Pre-Rx). Protein, urine (Qualitative): &gt;=2 (If Pre-Rx &gt;=1, &gt;=2*Pre-Rx). Red Blood Cells (RBC), urine (RBC per High Power Field (hpf)): &gt;=2 (If Pre-Rx&gt;=2, &gt;=4). White Blood Cells (WBC), urine (hpf): &gt;=2 (If Pre-Rx&gt;=2, &gt;=4).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablet, Oral, 2.5 mg, Single-dose</description>
    <arm_group_label>Dapagliflozin 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablet, Oral, 5 mg, Single-dose</description>
    <arm_group_label>Dapagliflozin 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablet, Oral, 10 mg, Single-dose</description>
    <arm_group_label>Dapagliflozin 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of T2DM

          -  Male and female subjects ages 10-17

          -  Glycosylated Hemoglobin A1c (HbA1c) ≥6 to 10%

          -  Body weight ≥30 kg

        Exclusion Criteria:

          -  Fasting plasma glucose (FPG) &gt;240 mg/dL at screening

          -  Abnormal renal function

          -  Active liver disease and/or significant abnormal liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children Hospital Of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Childrens Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lsuhsc-Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women And Children'S Hopsital Of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Promedica Toledo Children'S Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Children'S Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children'S Hospital Of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children'S Hospital Of Pittsburgh Of Upmc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Le Bonheur Hlthcare</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christus Santa Rosa Childrens Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44150</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <results_first_submitted>September 29, 2016</results_first_submitted>
  <results_first_submitted_qc>September 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2016</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>53 participants enrolled; 24 randomized; 24 treated with study drug. 29 participants were not randomized due to no longer meeting study criteria (25), withdrawal of consent (2), or other reasons (2).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin 2.5 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin 5 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
        </group>
        <group group_id="P3">
          <title>Dapagliflozin 10 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated participants</population>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin 2.5 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin 5 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
        </group>
        <group group_id="B3">
          <title>Dapagliflozin 10 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.0" spread="1.69"/>
                    <measurement group_id="B2" value="14.0" spread="2.39"/>
                    <measurement group_id="B3" value="14.6" spread="2.13"/>
                    <measurement group_id="B4" value="14.5" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>10 to &lt;= 15 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 to &lt;= 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin</title>
        <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of Dapagliflozin over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable pharmacokinetic (PK) profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin</title>
          <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of Dapagliflozin over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
          <population>All treated participants with evaluable pharmacokinetic (PK) profiles</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="34"/>
                    <measurement group_id="O2" value="48.4" spread="41"/>
                    <measurement group_id="O3" value="118" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin</title>
        <description>Time of maximum observed plasma concentration (Tmax) for Dapagliflozin was derived from plasma concentrations versus time data. Medians were reported in hours (h).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin</title>
          <description>Time of maximum observed plasma concentration (Tmax) for Dapagliflozin was derived from plasma concentrations versus time data. Medians were reported in hours (h).</description>
          <population>All treated participants with evaluable PK profiles.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.75" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.960" lower_limit="0.58" upper_limit="1.53"/>
                    <measurement group_id="O3" value="0.875" lower_limit="0.75" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Dapagliflozin</title>
        <description>Area under the plasma concentration-time curve from time zero extrapolated to infinite time was derived from concentration versus time data. Geometric means are reported in nanogram hours per milliliter (ng*hr/mL).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Dapagliflozin</title>
          <description>Area under the plasma concentration-time curve from time zero extrapolated to infinite time was derived from concentration versus time data. Geometric means are reported in nanogram hours per milliliter (ng*hr/mL).</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" spread="23"/>
                    <measurement group_id="O2" value="199" spread="29"/>
                    <measurement group_id="O3" value="427" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Dapagliflozin</title>
        <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of Dapagliflozin over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Dapagliflozin</title>
          <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of Dapagliflozin over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="27"/>
                    <measurement group_id="O2" value="189" spread="31"/>
                    <measurement group_id="O3" value="418" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Plasma Half-life (T-HALF) of Dapagliflozin</title>
        <description>Plasma half-life (T-Half) for Dapagliflozin was derived from plasma concentrations versus time data. Means are reported in hours.</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Half-life (T-HALF) of Dapagliflozin</title>
          <description>Plasma half-life (T-Half) for Dapagliflozin was derived from plasma concentrations versus time data. Means are reported in hours.</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="5.59"/>
                    <measurement group_id="O2" value="10.3" spread="3.72"/>
                    <measurement group_id="O3" value="10.7" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Apparent Clearance After Extravascular Administration (CL/F) of Dapagliflozin</title>
        <description>Apparent clearance after extravascular administration (CL/F) of Dapagliflozin was derived from plasma concentrations versus time data. Geometric means are reported in milliliters per minute (mL/min).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Apparent Clearance After Extravascular Administration (CL/F) of Dapagliflozin</title>
          <description>Apparent clearance after extravascular administration (CL/F) of Dapagliflozin was derived from plasma concentrations versus time data. Geometric means are reported in milliliters per minute (mL/min).</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413" spread="26"/>
                    <measurement group_id="O2" value="418" spread="27"/>
                    <measurement group_id="O3" value="391" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean of Apparent Volume of Distribution at Terminal Phase After Extravascular Administration (Vz/F) of Dapagliflozin</title>
        <description>Geometric mean of apparent volume of distribution at terminal phase after extravascular administration of Dapagliflozin was derived from plasma concentration versus time data. Geometric means are reported in Liters (L)</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Apparent Volume of Distribution at Terminal Phase After Extravascular Administration (Vz/F) of Dapagliflozin</title>
          <description>Geometric mean of apparent volume of distribution at terminal phase after extravascular administration of Dapagliflozin was derived from plasma concentration versus time data. Geometric means are reported in Liters (L)</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="468" spread="34"/>
                    <measurement group_id="O2" value="343" spread="45"/>
                    <measurement group_id="O3" value="355" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin 3-O-Glucuronide</title>
        <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of Dapagliflozin 3-O-Glucuronide over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin 3-O-Glucuronide</title>
          <description>Maximum observed plasma concentration (Cmax) was measured by plasma concentration of Dapagliflozin 3-O-Glucuronide over time. The geometric means are reported in nanograms per milliliter (ng/mL).</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="45"/>
                    <measurement group_id="O2" value="49.0" spread="50"/>
                    <measurement group_id="O3" value="154" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin 3-O-Glucuronide</title>
        <description>Time of maximum observed plasma concentration (Tmax) for Dapagliflozin 3-O-Glucuronide was derived from plasma concentrations versus time data. Medians were reported in hours (h).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin 3-O-Glucuronide</title>
          <description>Time of maximum observed plasma concentration (Tmax) for Dapagliflozin 3-O-Glucuronide was derived from plasma concentrations versus time data. Medians were reported in hours (h).</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.50" lower_limit="0.83" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.50" lower_limit="1.47" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Dapagliflozin 3-O-Glucuronide</title>
        <description>Area under the plasma concentration-time curve from time zero extrapolated to infinite time was derived from concentration versus time data. Geometric means are reported in nanogram hours per milliliter (ng*hr/mL).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Dapagliflozin 3-O-Glucuronide</title>
          <description>Area under the plasma concentration-time curve from time zero extrapolated to infinite time was derived from concentration versus time data. Geometric means are reported in nanogram hours per milliliter (ng*hr/mL).</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="23"/>
                    <measurement group_id="O2" value="232" spread="30"/>
                    <measurement group_id="O3" value="658" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Dapagliflozin 3-O-Glucuronide</title>
        <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of Dapagliflozin 3-O-Glucuronide over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Dapagliflozin 3-O-Glucuronide</title>
          <description>Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T)) was measured by plasma concentration of Dapagliflozin 3-O-Glucuronide over time. The geometric means are reported in nanogram hours per milliliter (ng*h/mL).</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" spread="20"/>
                    <measurement group_id="O2" value="208" spread="32"/>
                    <measurement group_id="O3" value="612" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Half-life (T-HALF) of Dapagliflozin 3-O-Glucuronide</title>
        <description>Plasma half-life (T-Half) for Dapagliflozin was derived from plasma concentration versus time data. Means are reported in hours.</description>
        <time_frame>11 time points: Immediately pre-dose, 0.5, 0.75, 1.0, 1.5, 4, 8, 12, 14, 24, and 48 hours post-dose</time_frame>
        <population>All treated participants with evaluable PK profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Half-life (T-HALF) of Dapagliflozin 3-O-Glucuronide</title>
          <description>Plasma half-life (T-Half) for Dapagliflozin was derived from plasma concentration versus time data. Means are reported in hours.</description>
          <population>All treated participants with evaluable PK profiles</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="3.086"/>
                    <measurement group_id="O2" value="8.71" spread="2.024"/>
                    <measurement group_id="O3" value="8.37" spread="3.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Fasting Plasma Glucose Concentrations at Pre-dose on Day 1 and on Day 2 After an 8-hr Fasting</title>
        <description>Plasma glucose concentrations were evaluated in all treated subjects at Day 1 pre-dose and at Day 2 after fasting for 8 hours. Means are reported in milligrams per deciliter (mg/dL).</description>
        <time_frame>Day 1 (Pre-dose) to Day 2</time_frame>
        <population>All treated participants with evaluable pharmacodynamic (PD) profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fasting Plasma Glucose Concentrations at Pre-dose on Day 1 and on Day 2 After an 8-hr Fasting</title>
          <description>Plasma glucose concentrations were evaluated in all treated subjects at Day 1 pre-dose and at Day 2 after fasting for 8 hours. Means are reported in milligrams per deciliter (mg/dL).</description>
          <population>All treated participants with evaluable pharmacodynamic (PD) profiles</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Pre-dose (n= 6, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.2" spread="72.56"/>
                    <measurement group_id="O2" value="152.1" spread="49.06"/>
                    <measurement group_id="O3" value="139.8" spread="39.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 after 8 hour fast (n= 3, 8, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" spread="45.21"/>
                    <measurement group_id="O2" value="119.4" spread="17.18"/>
                    <measurement group_id="O3" value="119.0" spread="29.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Fasting Plasma Glucose From Baseline Until Day 2</title>
        <description>Plasma glucose concentrations were evaluated in all treated subjects at Day 1 pre-dose and at Day 2 after fasting for 8 hours. Mean change from baseline to Day 2 is reported in milligrams per deciliter (mg/dL).</description>
        <time_frame>Day 1 (Pre-dose) to Day 2</time_frame>
        <population>All treated participants with evaluable PD profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Fasting Plasma Glucose From Baseline Until Day 2</title>
          <description>Plasma glucose concentrations were evaluated in all treated subjects at Day 1 pre-dose and at Day 2 after fasting for 8 hours. Mean change from baseline to Day 2 is reported in milligrams per deciliter (mg/dL).</description>
          <population>All treated participants with evaluable PD profiles</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.7" spread="60.08"/>
                    <measurement group_id="O2" value="-32.8" spread="42.41"/>
                    <measurement group_id="O3" value="-22.0" spread="27.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Total Amount of Glucose Excreted in Urine Over 24 Hours</title>
        <description>The total amount of glucose excreted in urine was measured for 24 hours following administration of Dapagliflozin. Means are reported in grams.</description>
        <time_frame>Time of dose to 24 hours post-dose, Day 1 to Day 2</time_frame>
        <population>All treated participants with evaluable PD profiles</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Total Amount of Glucose Excreted in Urine Over 24 Hours</title>
          <description>The total amount of glucose excreted in urine was measured for 24 hours following administration of Dapagliflozin. Means are reported in grams.</description>
          <population>All treated participants with evaluable PD profiles</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.84" spread="27.18"/>
                    <measurement group_id="O2" value="62.39" spread="26.55"/>
                    <measurement group_id="O3" value="89.04" spread="41.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vital Sign Abnormalities, Electrocardiogram (ECG) Abnormalities, or Physical Examination Abnormalities Following Study Drug Administration.</title>
        <description>Participants were followed from dosing on Day 1 until study discharge on Day 3. The number of participants with investigator-assessed clinically-important abnormalities in vital sign measurements, ECGs or physical examinations was reported.</description>
        <time_frame>Day 1 to Day 3</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Abnormalities, Electrocardiogram (ECG) Abnormalities, or Physical Examination Abnormalities Following Study Drug Administration.</title>
          <description>Participants were followed from dosing on Day 1 until study discharge on Day 3. The number of participants with investigator-assessed clinically-important abnormalities in vital sign measurements, ECGs or physical examinations was reported.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vital sign abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical examination abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Hematology Laboratory Abnormalities</title>
        <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose (Day -1). Lab values that met the following criteria were marked as abnormalities: Hemoglobin (grams per deciliter:g/dL): &lt;0.85*Pre-Rx. Hematocrit (%): &lt;0.85*Pre-Rx. Platelet Count (x10^9 cells per liter:c/L): &lt;0.85*LLN or &gt;1.5*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx). Leukocytes (x10^3 cells per microliter: c/uL): &lt;0.9*LLN, &gt;1.2*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx or &gt;ULN, if Pre- Rx&gt;ULN, use &gt;1.15*Pre-Rx or &lt;LLN). Neutrophils (Absolute) (x10^3 c/uL): &lt;=1.5. Lymphocytes (Absolute) (x10^3 c/uL): &lt;0.75 or &gt;7.5. Monocytes (Absolute) (x10^3 c/uL): &gt;2.000. Basophils (x10^3 c/uL): &gt;0.4. Eosinophils (Absolute) (x10^3 c/uL): &gt;0.75. Blasts (Absolute) (x10^9 c/L) &gt; 0.</description>
        <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Hematology Laboratory Abnormalities</title>
          <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose (Day -1). Lab values that met the following criteria were marked as abnormalities: Hemoglobin (grams per deciliter:g/dL): &lt;0.85*Pre-Rx. Hematocrit (%): &lt;0.85*Pre-Rx. Platelet Count (x10^9 cells per liter:c/L): &lt;0.85*LLN or &gt;1.5*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx). Leukocytes (x10^3 cells per microliter: c/uL): &lt;0.9*LLN, &gt;1.2*ULN (if Pre-Rx&lt;LLN, use &lt;0.85*Pre-Rx or &gt;ULN, if Pre- Rx&gt;ULN, use &gt;1.15*Pre-Rx or &lt;LLN). Neutrophils (Absolute) (x10^3 c/uL): &lt;=1.5. Lymphocytes (Absolute) (x10^3 c/uL): &lt;0.75 or &gt;7.5. Monocytes (Absolute) (x10^3 c/uL): &gt;2.000. Basophils (x10^3 c/uL): &gt;0.4. Eosinophils (Absolute) (x10^3 c/uL): &gt;0.75. Blasts (Absolute) (x10^9 c/L) &gt; 0.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes, low (n=8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, low (n=8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Serum Chemistry Abnormalities</title>
        <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx). Bilirubin (milligrams per deciliter: mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx). Blood Urea Nitrogen (mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.2*Pre-Rx). Creatinine (micromoles per Liter (umol/L)): &gt;1.5*ULN if Pre-Rx missing or &lt;= ULN, &gt;1.33*Pre-Rx if PreRx &gt; ULN. Sodium (mmol/L): &gt;1.05*ULN, 1.05*Pre-Rx if Pre-Rx&gt;ULN: &lt;0.95*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.05*Pre-Rx, &lt;LLN). Potassium(mmol/L), Chloride (mmol/L), Calcium(mmol/L): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN). Phosphorus (mg/dL): &lt;0.85*LLN, &gt;1.25*ULN (if Pre-Rx&lt;LLN, &lt;0.85*Pre-Rx, &gt;ULN. if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx, &lt;LLN).</description>
        <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Serum Chemistry Abnormalities</title>
          <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Alkaline Phosphatase (units per liter: U/L), Aspartate Aminotransferase (U/L), Alanine Aminotransferase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx). Bilirubin (milligrams per deciliter: mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.25*Pre-Rx). Blood Urea Nitrogen (mg/dL): &gt;1.1*ULN (if Pre-Rx&gt;ULN, use &gt;1.2*Pre-Rx). Creatinine (micromoles per Liter (umol/L)): &gt;1.5*ULN if Pre-Rx missing or &lt;= ULN, &gt;1.33*Pre-Rx if PreRx &gt; ULN. Sodium (mmol/L): &gt;1.05*ULN, 1.05*Pre-Rx if Pre-Rx&gt;ULN: &lt;0.95*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.05*Pre-Rx, &lt;LLN). Potassium(mmol/L), Chloride (mmol/L), Calcium(mmol/L): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN). Phosphorus (mg/dL): &lt;0.85*LLN, &gt;1.25*ULN (if Pre-Rx&lt;LLN, &lt;0.85*Pre-Rx, &gt;ULN. if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx, &lt;LLN).</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, high (8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, high (n=8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Abnormalities in Other Chemistry Testing</title>
        <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Glucose, fasting serum (mmol/L): &lt;0.8*LLN, &gt;1.3*ULN (if Pre-Rx&lt;LLN: &lt;0.8*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;2.0*Pre-Rx, &lt;LLN). Protein (grams per deciliter: g/L): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN). Albumin (g/L): &lt;0.9*LLN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx). Uric Acid (mmol/L): &gt;1.2*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx). Lactate Dehydrogenase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx)</description>
        <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Abnormalities in Other Chemistry Testing</title>
          <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Glucose, fasting serum (mmol/L): &lt;0.8*LLN, &gt;1.3*ULN (if Pre-Rx&lt;LLN: &lt;0.8*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;2.0*Pre-Rx, &lt;LLN). Protein (grams per deciliter: g/L): &lt;0.9*LLN, &gt;1.1*ULN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx, &gt;ULN. If Pre-Rx&gt;ULN: &gt;1.1*Pre-Rx, &lt;LLN). Albumin (g/L): &lt;0.9*LLN (if Pre-Rx&lt;LLN: &lt;0.9*Pre-Rx). Uric Acid (mmol/L): &gt;1.2*ULN (if Pre-Rx&gt;ULN: &gt;1.25*Pre-Rx). Lactate Dehydrogenase (U/L): &gt;1.25*ULN (if Pre-Rx&gt;ULN: &gt;1.5*Pre-Rx)</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, fasting serum, high (n=7, 7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional other chemistry marked abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Urinalysis Abnormalities</title>
        <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Blood, urine (Qualitative): &gt;=2 (If Pre-Rx &gt;= 1, &gt;=2*Pre-Rx). Glucose, urine (Qualitative): &gt;=1, (If Pre-Rx &gt;=1, &gt;=2*Pre-Rx). Protein, urine (Qualitative): &gt;=2 (If Pre-Rx &gt;=1, &gt;=2*Pre-Rx). Red Blood Cells (RBC), urine (RBC per High Power Field (hpf)): &gt;=2 (If Pre-Rx&gt;=2, &gt;=4). White Blood Cells (WBC), urine (hpf): &gt;=2 (If Pre-Rx&gt;=2, &gt;=4).</description>
        <time_frame>Day 1 (Pre-dose) to Day 3</time_frame>
        <population>All treated participants with evaluable lab results</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 2.5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 5 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
          </group>
          <group group_id="O3">
            <title>Dapagliflozin 10 mg</title>
            <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Urinalysis Abnormalities</title>
          <description>LLN=Lower Limit of Normal, ULN=Upper Limit of Normal, Pre-Rx=Value before first dose. Lab values that met the following criteria were marked as abnormalities: Blood, urine (Qualitative): &gt;=2 (If Pre-Rx &gt;= 1, &gt;=2*Pre-Rx). Glucose, urine (Qualitative): &gt;=1, (If Pre-Rx &gt;=1, &gt;=2*Pre-Rx). Protein, urine (Qualitative): &gt;=2 (If Pre-Rx &gt;=1, &gt;=2*Pre-Rx). Red Blood Cells (RBC), urine (RBC per High Power Field (hpf)): &gt;=2 (If Pre-Rx&gt;=2, &gt;=4). White Blood Cells (WBC), urine (hpf): &gt;=2 (If Pre-Rx&gt;=2, &gt;=4).</description>
          <population>All treated participants with evaluable lab results</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood, urine, high (n=8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, urine, high (n=8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, urine, high (n=8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, urine, high (n=1, 1, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, urine, high (n=4, 2, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs collected from Screening (up to 28 days before first dose) to 30 days after last dose; Non-serious AEs collected from time of dose (Day 1) to Study Discharge (Day 3) and followed until resolution, stabilization, or reclassification as SAE.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin 2.5 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 2.5 mg, Single-dose</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin 5 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 5 mg, Single-dose</description>
        </group>
        <group group_id="E3">
          <title>Dapagliflozin 10 mg</title>
          <description>Dapagliflozin: Tablet, Oral, 10 mg, Single-dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Maria Langkilde</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

